JP2021500028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500028A5 JP2021500028A5 JP2020522004A JP2020522004A JP2021500028A5 JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5 JP 2020522004 A JP2020522004 A JP 2020522004A JP 2020522004 A JP2020522004 A JP 2020522004A JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence represented
- represented
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 108091026890 Coding region Proteins 0.000 claims 30
- 238000000034 method Methods 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 206010022000 influenza Diseases 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 230000036436 anti-hiv Effects 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000003097 anti-respiratory effect Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 229950004283 actoxumab Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001512 anti-cytomegaloviral effect Effects 0.000 claims 1
- 230000003622 anti-hsv Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023190846A JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575275P | 2017-10-20 | 2017-10-20 | |
| US62/575,275 | 2017-10-20 | ||
| US201762580303P | 2017-11-01 | 2017-11-01 | |
| US62/580,303 | 2017-11-01 | ||
| US201862623371P | 2018-01-29 | 2018-01-29 | |
| US62/623,371 | 2018-01-29 | ||
| PCT/US2018/056789 WO2019079772A1 (en) | 2017-10-20 | 2018-10-19 | SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Division JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500028A JP2021500028A (ja) | 2021-01-07 |
| JP2021500028A5 true JP2021500028A5 (https=) | 2021-11-25 |
| JP7383607B2 JP7383607B2 (ja) | 2023-11-20 |
Family
ID=66174267
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522004A Active JP7383607B2 (ja) | 2017-10-20 | 2018-10-19 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11578118B2 (https=) |
| EP (1) | EP3697895A4 (https=) |
| JP (3) | JP7383607B2 (https=) |
| KR (2) | KR20240156649A (https=) |
| CN (2) | CN111479916B (https=) |
| AU (2) | AU2018351072B9 (https=) |
| BR (1) | BR112020007823A2 (https=) |
| CA (1) | CA3079681A1 (https=) |
| IL (1) | IL274082B2 (https=) |
| MX (1) | MX2020004063A (https=) |
| SG (1) | SG11202003024WA (https=) |
| WO (1) | WO2019079772A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108486125B (zh) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在制备人源单域抗体中的应用 |
| WO2020053865A1 (en) * | 2018-09-13 | 2020-03-19 | Ramot At Tel-Aviv University Ltd. | Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion |
| CN111995674B (zh) * | 2020-09-03 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用 |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| US20250302998A1 (en) * | 2022-05-09 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2025096483A2 (en) * | 2023-10-30 | 2025-05-08 | Be Biopharma, Inc. | Engineered cell preparations |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| AU2001238079A1 (en) | 2000-02-09 | 2001-08-20 | Med Immune, Inc. | Antibody gene therapy with adeno-associated viral vectors |
| KR100545945B1 (ko) * | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| DE10113776B4 (de) * | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| WO2006115800A2 (en) * | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| AU2007245164A1 (en) * | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-IGF-IR antibodies and uses thereof |
| US20120102582A1 (en) | 2009-04-03 | 2012-04-26 | Haynes Barton F | Mouse models |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| AU2010310895A1 (en) | 2009-10-23 | 2012-05-03 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using same |
| US9074223B2 (en) * | 2010-01-08 | 2015-07-07 | Immusoft Corporation | Vectors and methods for transducing B cells |
| BR112012031638B1 (pt) | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| US8637024B2 (en) | 2010-11-12 | 2014-01-28 | The Rockefeller University | Fusion antibodies for HIV therapy |
| EP2663334A4 (en) | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
| NO2748201T3 (https=) | 2011-08-23 | 2018-05-12 | ||
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| CA2867522A1 (en) | 2012-03-16 | 2013-09-19 | University Of Rochester | Methods of predicting clinical outcome of chronic lymphocytic leukemia |
| WO2013148256A2 (en) | 2012-03-27 | 2013-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the generation of immunoglobulin sequences |
| AU2013293270B2 (en) | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3031921B1 (en) | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| WO2014141192A1 (en) * | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| MX374532B (es) | 2013-06-17 | 2025-03-06 | Broad Inst Inc | Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos. |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| CN105683379A (zh) | 2013-06-17 | 2016-06-15 | 布罗德研究所有限公司 | 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化 |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| RU2716420C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
| EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| JP6595988B2 (ja) | 2013-07-19 | 2019-10-23 | ヴィブ ブイゼットダブリュー | ターゲットされる修飾ｔｎｆファミリーメンバー |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| SG10201804975PA (en) * | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| WO2015089427A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
| EP3470089A1 (en) | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| JP6712948B2 (ja) | 2013-12-12 | 2020-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法 |
| EP3080259B1 (en) | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| JP7103750B2 (ja) | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| WO2015120056A1 (en) | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| ES2755957T3 (es) | 2014-03-31 | 2020-04-24 | Univ Texas | Anticuerpos de tos ferina humanizados y usos de los mismos |
| US11897921B2 (en) | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| CA2981077A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US12110490B2 (en) | 2015-12-18 | 2024-10-08 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| JP6914274B2 (ja) | 2016-01-22 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | Ｃｒｉｓｐｒｃｐｆ１の結晶構造 |
-
2018
- 2018-10-19 CA CA3079681A patent/CA3079681A1/en active Pending
- 2018-10-19 KR KR1020247035275A patent/KR20240156649A/ko active Pending
- 2018-10-19 AU AU2018351072A patent/AU2018351072B9/en active Active
- 2018-10-19 WO PCT/US2018/056789 patent/WO2019079772A1/en not_active Ceased
- 2018-10-19 CN CN201880080021.5A patent/CN111479916B/zh active Active
- 2018-10-19 KR KR1020207014413A patent/KR102723182B1/ko active Active
- 2018-10-19 EP EP18869188.5A patent/EP3697895A4/en active Pending
- 2018-10-19 BR BR112020007823-9A patent/BR112020007823A2/pt unknown
- 2018-10-19 IL IL274082A patent/IL274082B2/en unknown
- 2018-10-19 MX MX2020004063A patent/MX2020004063A/es unknown
- 2018-10-19 US US16/757,707 patent/US11578118B2/en active Active
- 2018-10-19 CN CN202411382074.6A patent/CN119265240A/zh active Pending
- 2018-10-19 SG SG11202003024WA patent/SG11202003024WA/en unknown
- 2018-10-19 JP JP2020522004A patent/JP7383607B2/ja active Active
-
2023
- 2023-02-08 US US18/166,151 patent/US12589145B2/en active Active
- 2023-11-08 JP JP2023190846A patent/JP7650336B2/ja active Active
-
2024
- 2024-11-12 AU AU2024264571A patent/AU2024264571A1/en active Pending
-
2025
- 2025-03-11 JP JP2025038002A patent/JP2025090718A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500028A5 (https=) | ||
| US20220363771A1 (en) | Multispecific antibodies | |
| KR20100034015A (ko) | 알레르기 질환 치료를 위한 방법 및 조성물 | |
| JP7650336B2 (ja) | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 | |
| CN106573986A (zh) | 多特异性抗体 | |
| JP2022540083A (ja) | バイオフィルムを破壊するための抗体組成物 | |
| JP2024016201A5 (https=) | ||
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| JP2025134707A5 (https=) | ||
| US20180237502A1 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| CN113710688A (zh) | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) | |
| JP2022185053A (ja) | 腸内消化に対する改善された安定性を有する抗体 | |
| WO2022060906A1 (en) | Coronavirus antibodies and uses thereof | |
| EP4628095A1 (en) | Fusion protein and granulated antigen comprising same | |
| CN109929033A (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| US12460010B2 (en) | Antibodies that bind TNFRSF25 | |
| JP2025500806A5 (https=) | ||
| JP2024546759A5 (https=) | ||
| JP2025500805A5 (https=) | ||
| CN101896502B (zh) | 抗人TNFα单抗、分子进化及其应用 | |
| CN103087155A (zh) | 一种狂犬病毒疫苗增效蛋白及编码该蛋白的基因和应用 | |
| WO2017156423A2 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
| EP3525813B1 (en) | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop | |
| CN120399078B (zh) | 靶向cd117的纳米抗体及其应用 |